Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry
D Das, J Hong - European Journal of Medicinal Chemistry, 2019 - Elsevier
The 4-aminoquinazoline core is an interesting pharmacophore and its applications in
medicinal chemistry are wide spread. The core has been used for making many kinase …
medicinal chemistry are wide spread. The core has been used for making many kinase …
Implementing personalized medicine in a cancer center
DA Fenstermacher, RM Wenham, DE Rollison… - The Cancer …, 2011 - journals.lww.com
Abstract In 2006, the Moffitt Cancer Center partnered with patients, community clinicians,
industry, academia, and 17 hospitals in the United States to begin a personalized cancer …
industry, academia, and 17 hospitals in the United States to begin a personalized cancer …
Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent
The synthesis of some 2-furano-4 (3H)-quinazolinones, diamides (open ring quinazolines),
quinoxalines and their biological evaluation as antitumor agents using National Cancer …
quinoxalines and their biological evaluation as antitumor agents using National Cancer …
The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer
FE Lennon, T Mirzapoiazova, B Mambetsariev… - PloS one, 2014 - journals.plos.org
Recent epidemiologic studies implying differences in cancer recurrence based on
anesthetic regimens raise the possibility that the mu opioid receptor (MOR) can influence …
anesthetic regimens raise the possibility that the mu opioid receptor (MOR) can influence …
Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study
Novel derivatives of quinazoline (1–27) have been synthesized and tested for their antitumor
activity against three tumor cell lines among these cell lines the human breast carcinoma …
activity against three tumor cell lines among these cell lines the human breast carcinoma …
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Recent studies have demonstrated that some patients with chronic myeloid leukemia (CML)
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
Increased μ-opioid receptor expression in metastatic lung cancer
PA Singleton, T Mirzapoiazova, R Hasina… - British journal of …, 2014 - academic.oup.com
Background We and others have previously demonstrated that the μ-opioid receptor (MOR)
is overexpressed in several human malignancies. There is a seven-fold increase in MOR in …
is overexpressed in several human malignancies. There is a seven-fold increase in MOR in …
MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma
Conclusion Over the past two decades, noteworthy progress has been emphasized in
NSCLC treatment. A better understanding of the cancer biology has allowed the …
NSCLC treatment. A better understanding of the cancer biology has allowed the …
An update on emerging drugs in osteosarcoma: towards tailored therapies?
CM Hattinger, MP Patrizio, F Magagnoli… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: Current treatment of conventional and non-conventional high-grade
osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when …
osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when …
Synthesis and evaluation of 2, 7-diamino-thiazolo [4, 5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
R Lin, SG Johnson, PJ Connolly, SK Wetter… - Bioorganic & medicinal …, 2009 - Elsevier
2, 7-Diamino-thiazolo [4, 5-d] pyrimidine analogues were synthesized as novel epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors. Representative compounds …
growth factor receptor (EGFR) tyrosine kinase inhibitors. Representative compounds …